ME00962B - Benzimidazolski derivati - Google Patents

Benzimidazolski derivati

Info

Publication number
ME00962B
ME00962B MEP-2009-349A MEP34909A ME00962B ME 00962 B ME00962 B ME 00962B ME P34909 A MEP34909 A ME P34909A ME 00962 B ME00962 B ME 00962B
Authority
ME
Montenegro
Prior art keywords
benzimidazole derivatives
mammals
compounds
treatment
cell growth
Prior art date
Application number
MEP-2009-349A
Other languages
English (en)
French (fr)
Inventor
Christopher Scott Jones
GRECA Susan LA
Qifang Li
Michael John Munchhof
Lawrence Alan Reiter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ME00962B publication Critical patent/ME00962B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

            Ovaj  izum odnosi  se na spoj Formule I (I) ili njegovu  farmaceutsk i  prihvatljivu so, gdje R1, R2, R3A, R3B, R4, R5, X, m i n su  definirani   u  ovoj  specifikaciji .  Takvi  novi  benzimidazolski  derivati   korisni  su  u  liječenju abnormalnog staničnog  rasta, poput raka, kod  sisavaca. Ovaj izum  također se  odnosi na postupak upotrebe takvih spojeva  u liječenju  abnormalnog staničnog rasta kod sisavaca, osobito ljudi , te na farmaceutske pripravke koji sadrže takve spojeve.
MEP-2009-349A 2007-06-29 2008-06-16 Benzimidazolski derivati ME00962B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02
PCT/IB2008/001575 WO2009004427A2 (en) 2007-06-29 2008-06-16 Benzimidazole derivatives

Publications (1)

Publication Number Publication Date
ME00962B true ME00962B (me) 2012-06-20

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-349A ME00962B (me) 2007-06-29 2008-06-16 Benzimidazolski derivati

Country Status (46)

Country Link
US (2) US8148401B2 (me)
EP (1) EP2170860B9 (me)
JP (2) JP4567099B2 (me)
KR (1) KR101143246B1 (me)
CN (1) CN101687841B (me)
AP (1) AP2377A (me)
AR (1) AR067346A1 (me)
AU (1) AU2008272641B2 (me)
BR (1) BRPI0813412B8 (me)
CA (1) CA2690953C (me)
CL (1) CL2008001922A1 (me)
CO (1) CO6160232A2 (me)
CR (1) CR11150A (me)
CU (1) CU23847B1 (me)
CY (2) CY1118650T1 (me)
DK (1) DK2170860T5 (me)
DO (1) DOP2009000278A (me)
EA (1) EA016888B1 (me)
EC (1) ECSP099803A (me)
ES (1) ES2609258T3 (me)
FR (1) FR20C1038I2 (me)
GE (1) GEP20125702B (me)
GT (1) GT200900328A (me)
HK (1) HK1139658A1 (me)
HN (1) HN2008000974A (me)
HR (1) HRP20161562T2 (me)
HU (2) HUE030052T4 (me)
IL (1) IL202420A (me)
LT (2) LT2170860T (me)
MA (1) MA31466B1 (me)
ME (1) ME00962B (me)
MY (1) MY148636A (me)
NI (1) NI200900219A (me)
NL (1) NL301057I2 (me)
NO (1) NO2020027I1 (me)
NZ (1) NZ581889A (me)
PA (1) PA8785401A1 (me)
PE (2) PE20090772A1 (me)
PL (1) PL2170860T3 (me)
PT (1) PT2170860T (me)
RS (1) RS55395B9 (me)
SI (1) SI2170860T1 (me)
TN (1) TN2009000544A1 (me)
TW (1) TWI371451B (me)
UY (1) UY31164A1 (me)
WO (1) WO2009004427A2 (me)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00962B (me) 2007-06-29 2012-06-20 Pfizer Benzimidazolski derivati
EP2330894B8 (en) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
RU2533825C2 (ru) * 2009-06-11 2014-11-20 Сиена Байотек С.П.А. ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛА И ИМИДАЗО[4,5-с]ПИРИДИНА, В КАЧЕСТВЕ АНТАГОНИСТА ПУТИ HEDGEHOG
GEP20146075B (en) 2009-08-26 2014-04-10 Takeda Pharmaceuticals Co Fused heterocyclic ring derivative and usage thereof
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Ｎｔｔドコモ ホーム基地局及びハンドオーバ方法
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
DK2680694T3 (en) 2011-02-28 2019-03-25 Biomarin Pharm Inc HISTONDEACETYLASE INHIBITORS
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2684167B1 (en) 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
JP6163156B2 (ja) * 2011-09-26 2017-07-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ リゾホスファチジン酸（ｌｐａ）受容体アンタゴニストとしてのベンジルピペリジン化合物
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2014081953A1 (en) 2012-11-21 2014-05-30 Richard David J Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
AU2014228344C1 (en) 2013-03-15 2019-02-07 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10435364B2 (en) 2013-04-17 2019-10-08 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
KR20190038677A (ko) 2015-04-24 2019-04-08 화이자 인코포레이티드 1-((2r,4r)-2-(1h-벤조[d]이미다졸-2-일)-1-메틸피페리딘-4-일)-3-(4-시아노페닐)우레아 말레에이트의 결정질 형태
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2020164722A (ja) * 2019-03-29 2020-10-08 デクセリアルズ株式会社 接着剤組成物
HRP20240302T1 (hr) 2020-01-28 2024-05-10 Assia Chemical Industries Ltd Postupci za pripremu glasdegiba i njegove soli i krutih oblika glasdegib maleata i postupak za njihovu pripremu
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
EP4126237B1 (en) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
CN115997122A (zh) 2020-06-26 2023-04-21 拉夸里亚创药株式会社 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354397B2 (en) * 2001-07-27 2013-01-15 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1499607B1 (en) * 2001-12-04 2005-12-07 Actelion Pharmaceuticals Ltd. 4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP2006505570A (ja) 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
WO2005042495A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
NZ547109A (en) 2003-10-28 2010-03-26 Vertex Pharma Benzimidazoles useful as modulators of ion channels
WO2006050506A1 (en) * 2004-11-03 2006-05-11 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE102005012875B4 (de) * 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2008064830A1 (en) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
ME00962B (me) 2007-06-29 2012-06-20 Pfizer Benzimidazolski derivati
WO2009154739A2 (en) 2008-06-17 2009-12-23 Duke University Smoothened receptor modulators
BRPI0917936A2 (pt) 2008-08-25 2017-07-11 Irm Llc Moduladores de via hedgehog

Also Published As

Publication number Publication date
TN2009000544A1 (fr) 2011-03-31
TW200911792A (en) 2009-03-16
BRPI0813412B8 (pt) 2021-05-25
CR11150A (es) 2010-02-08
HK1139658A1 (en) 2010-09-24
DOP2009000278A (es) 2009-12-31
CU20090225A7 (es) 2012-02-15
FR20C1038I1 (me) 2020-10-02
IL202420A0 (en) 2010-06-30
ECSP099803A (es) 2010-01-29
US8148401B2 (en) 2012-04-03
KR101143246B1 (ko) 2012-05-18
CN101687841B (zh) 2013-07-10
CU23847B1 (es) 2012-10-15
TWI371451B (en) 2012-09-01
HUE030052T4 (en) 2017-06-28
US20090005416A1 (en) 2009-01-01
HRP20161562T1 (hr) 2016-12-30
PE20121010A1 (es) 2012-08-06
AR067346A1 (es) 2009-10-07
DK2170860T3 (en) 2017-01-09
UY31164A1 (es) 2009-01-30
AU2008272641B2 (en) 2013-08-29
MA31466B1 (fr) 2010-06-01
AU2008272641A1 (en) 2009-01-08
EP2170860B9 (en) 2017-02-22
JP2010531869A (ja) 2010-09-30
CL2008001922A1 (es) 2009-01-02
BRPI0813412A2 (pt) 2014-12-30
EP2170860B1 (en) 2016-11-02
GT200900328A (es) 2011-08-29
FR20C1038I2 (fr) 2021-08-13
MY148636A (en) 2013-05-15
AP2377A (en) 2012-03-07
GEP20125702B (en) 2012-12-10
JP4567099B2 (ja) 2010-10-20
EA016888B1 (ru) 2012-08-30
NO2020027I1 (no) 2020-08-11
HRP20161562T2 (hr) 2017-04-21
JP2010280693A (ja) 2010-12-16
US20120157495A1 (en) 2012-06-21
LTPA2020528I1 (lt) 2020-09-25
KR20100028120A (ko) 2010-03-11
CY2020028I2 (el) 2020-11-25
IL202420A (en) 2014-05-28
LTC2170860I2 (lt) 2022-03-10
RS55395B1 (sr) 2017-04-28
NL301057I2 (nl) 2020-09-10
EP2170860A2 (en) 2010-04-07
WO2009004427A2 (en) 2009-01-08
CY2020028I1 (el) 2020-11-25
HUS2000031I1 (hu) 2020-09-28
CO6160232A2 (es) 2010-05-20
CY1118650T1 (el) 2017-07-12
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
US8431597B2 (en) 2013-04-30
EA200971104A1 (ru) 2010-06-30
CN101687841A (zh) 2010-03-31
HUE030052T2 (hu) 2017-04-28
HN2008000974A (es) 2011-01-24
CA2690953A1 (en) 2009-01-08
NZ581889A (en) 2011-05-27
RS55395B9 (sr) 2020-01-31
WO2009004427A3 (en) 2009-06-04
DK2170860T5 (en) 2017-03-20
SI2170860T1 (sl) 2017-01-31
LT2170860T (lt) 2017-01-10
AP2009005089A0 (en) 2009-12-31
CA2690953C (en) 2012-10-02
NL301057I1 (nl) 2020-07-22
BRPI0813412B1 (pt) 2020-01-21
ES2609258T3 (es) 2017-04-19
PL2170860T3 (pl) 2017-05-31
PA8785401A1 (es) 2009-01-23
PT2170860T (pt) 2017-01-04

Similar Documents

Publication Publication Date Title
ME00962B (me) Benzimidazolski derivati
EA201170772A1 (ru) Органические соединения
NO20090295L (no) Substituerte heteroarylderivater
EA201100503A1 (ru) Глюкозидные производные и их применения
MX2009011090A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
EA200970156A1 (ru) Пиридизиноновые производные
RS51661B (en) NEW DIOSMETHINE DERIVATIVES, THE PROCEDURE FOR THEIR MAKING AND THE PHARMACEUTICAL MIXTURES CONTAINING THEM
NI200800294A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen.
UA107175C2 (uk) Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
BRPI0915084B8 (pt) composto, e, composição farmacêutica
TW200732323A (en) Organic compounds
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201101026A1 (ru) Ингибиторы бета-секретазы
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA200601273A1 (ru) Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
JO2734B1 (en) Organic compounds
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
NO20085317L (no) Imidazoazepinonforbindelser
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA201290229A1 (ru) Производные спиролактама и их применение
UY29894A1 (es) Derivados del ácido (2-((2s)-2-hidroxipropil)oxi)fenil)acético y del ácido (2-((2s)-2-hidroxipropil)oxi)fenil) propanoico sustituidos, composiciones farmacéuticas conteniéndolo, procesos de preparación y aplicaciones
RS53002B (en) ANTI-CANCER UNIT AND PHARMACEUTICAL COPMOSITION CONTAINING IT